RU2012124093A - METHOD FOR INCREASING DENSITY OF DENDRITIC SPIKES - Google Patents
METHOD FOR INCREASING DENSITY OF DENDRITIC SPIKES Download PDFInfo
- Publication number
- RU2012124093A RU2012124093A RU2012124093/15A RU2012124093A RU2012124093A RU 2012124093 A RU2012124093 A RU 2012124093A RU 2012124093/15 A RU2012124093/15 A RU 2012124093/15A RU 2012124093 A RU2012124093 A RU 2012124093A RU 2012124093 A RU2012124093 A RU 2012124093A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- inhibitor
- binds
- patient
- epitope
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Abstract
1. Способ увеличения плотности дендритных шипиков в нейронах пациента с когнитивным или психическим расстройством, включающий введение указанному пациенту эффективного количества ингибитора DR6 или ингибитора р75.2. Способ по п.1, в котором указанным ингибитором DR6 является антитело, которое связывается с эпитопом DR6 и ингибирует функцию DR6.3. Способ по п.1, в котором указанным ингибитором р75 является антитело, которое связывается с эпитопом р75 и ингибирует функцию р75.4. Способ по п.2, в котором указанное антитело выбрано из группы, состоящей из 3F4.4.8, 4B6.9.7, 1E5.5.7, и их антиген-связывающих фрагментов.5. Способ по п.4, в котором указанным антителом является химерное или гуманизированное 3F4.4.8, 4B6.9.7 или 1E5.5.7, или антитело, которое связывает такой же эпитоп, как 3F4.4.8, 4B6.9.7 или 1E5.5.7.6. Способ по п.1, в котором указанный ингибитор DR6 снижает или предупреждает прохождение сигнала от DR6 в указанном нейроне.7. Способ по п.1, в котором указанный ингибитор р75 снижает или предупреждает прохождение сигнала от р75 в указанном нейроне.8. Способ лечения когнитивного или психического расстройства у нуждающегося в этом пациента, включающий идентификацию пациента, имеющего когнитивное или психическое расстройство, ассоциированное со снижением количества дендритных шипиков, и введение указанному пациенту терапевтически эффективного количества антагониста DR6 или антагониста р75.9. Способ по п.1 или 8, в котором указанное психическое или когнитивное расстройство выбрано из группы, состоящей из синдрома Ретта, синдрома Туретта, аутизма, шизофрении и умственной отсталости, связанной с синдромом хрупкой Х-хромосомы.10. Способ по п.8, в котором указанным ингиб�1. A method of increasing the density of dendritic spines in the neurons of a patient with a cognitive or mental disorder, comprising administering to said patient an effective amount of a DR6 inhibitor or p75.2 inhibitor. The method of claim 1, wherein said DR6 inhibitor is an antibody that binds to the DR6 epitope and inhibits the function of DR6.3. The method of claim 1, wherein said p75 inhibitor is an antibody that binds to the p75 epitope and inhibits p75.4 function. The method according to claim 2, wherein said antibody is selected from the group consisting of 3F4.4.8, 4B6.9.7, 1E5.5.7, and antigen-binding fragments thereof. The method of claim 4, wherein said antibody is a chimeric or humanized 3F4.4.8, 4B6.9.7 or 1E5.5.7, or an antibody that binds to the same epitope as 3F4.4.8, 4B6.9.7 or 1E5.5.7.6. The method of claim 1, wherein said DR6 inhibitor reduces or prevents the passage of a signal from DR6 in said neuron. The method of claim 1, wherein said p75 inhibitor reduces or prevents the passage of a signal from p75 in said neuron. A method of treating a cognitive or mental disorder in a patient in need thereof, comprising identifying a patient having a cognitive or mental disorder associated with a decrease in the number of dendritic spines, and administering to said patient a therapeutically effective amount of a DR6 antagonist or p75.9 antagonist. The method of claim 1 or 8, wherein said mental or cognitive disorder is selected from the group consisting of Rett syndrome, Tourette syndrome, autism, schizophrenia and mental retardation associated with the fragile X chromosome syndrome. The method of claim 8, wherein said inhib
Claims (23)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26081509P | 2009-11-12 | 2009-11-12 | |
US61/260,815 | 2009-11-12 | ||
US29402010P | 2010-01-11 | 2010-01-11 | |
US61/294,020 | 2010-01-11 | ||
PCT/US2010/056506 WO2011060246A2 (en) | 2009-11-12 | 2010-11-12 | A method of promoting dendritic spine density |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2012124093A true RU2012124093A (en) | 2013-12-20 |
Family
ID=43629094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012124093/15A RU2012124093A (en) | 2009-11-12 | 2010-11-12 | METHOD FOR INCREASING DENSITY OF DENDRITIC SPIKES |
Country Status (12)
Country | Link |
---|---|
US (1) | US20110110942A1 (en) |
EP (1) | EP2498817A2 (en) |
JP (1) | JP2013510871A (en) |
KR (1) | KR20120103587A (en) |
CN (1) | CN102612374A (en) |
AR (1) | AR078986A1 (en) |
BR (1) | BR112012009997A2 (en) |
CA (1) | CA2780319A1 (en) |
MX (1) | MX2012005464A (en) |
RU (1) | RU2012124093A (en) |
TW (1) | TW201121570A (en) |
WO (1) | WO2011060246A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090094854A (en) * | 2006-12-22 | 2009-09-08 | 제넨테크, 인크. | Dr6 antibodies inhibiting the binding of dr6 to app, and uses thereof in treating neurological disorders |
KR20110028504A (en) * | 2008-06-12 | 2011-03-18 | 제넨테크, 인크. | Method for screening for compounds that inhibit neurodegeneration |
CA2744043A1 (en) | 2008-11-25 | 2010-06-03 | Biogen Idec Ma Inc. | Use of dr6 and p75 antagonists to promote survival of cells of the nervous system |
JP6062362B2 (en) * | 2010-08-19 | 2017-01-18 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | Treatment of cognitive impairment associated with abnormal dendritic spines using PKC activators |
US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
WO2020202701A1 (en) * | 2019-03-29 | 2020-10-08 | 富士フイルム株式会社 | Cell evaluation device, cell evaluation device operation method, cell evaluation device operation program, and cell culturing system |
WO2020247336A1 (en) * | 2019-06-03 | 2020-12-10 | The Regents Of The University Of California | Pifithrin analogues and methods of treating rett syndrome |
US11571541B2 (en) | 2020-10-27 | 2023-02-07 | David Richardson Hubbard, JR. | Apparatus and methods of transcranial stimulation to adjust sensory cortical dendritic spine neck membrane potentials for altering consciousness |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US802125A (en) | 1903-12-15 | 1905-10-17 | Barrett D Tillinghast | Valve-gear for explosive-engines. |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (en) | 1978-01-06 | 1979-08-03 | David Bernard | DRYER FOR SCREEN-PRINTED SHEETS |
JPS6023084B2 (en) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | blood substitute |
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4943529A (en) | 1982-05-19 | 1990-07-24 | Gist-Brocades Nv | Kluyveromyces as a host strain |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (en) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Process for the biotechnical production of alkaline phosphatase |
AU3145184A (en) | 1983-08-16 | 1985-02-21 | Zymogenetics Inc. | High expression of foreign genes in schizosaccharomyces pombe |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
DE3675588D1 (en) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE). |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946783A (en) | 1987-01-30 | 1990-08-07 | President And Fellows Of Harvard College | Periplasmic protease mutants of Escherichia coli |
DE3702789A1 (en) | 1987-01-30 | 1988-08-18 | Bayer Ag | PROCUREMENT PROTEIN OF APC POLYPEPTIDE, FOR CODING DNA AND DIAGNOSTIC USE OF DNA AND PROTEIN |
US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
WO1989005859A1 (en) | 1987-12-21 | 1989-06-29 | The Upjohn Company | Agrobacterium mediated transformation of germinating plant seeds |
AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
FR2646437B1 (en) | 1989-04-28 | 1991-08-30 | Transgene Sa | NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME |
ATE144281T1 (en) | 1989-04-28 | 1996-11-15 | Rhein Biotech Proz & Prod Gmbh | YEAST CELLS OF THE GENUS SCHWANNIOMYCES |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
ES2096590T3 (en) | 1989-06-29 | 1997-03-16 | Medarex Inc | BI-SPECIFIC REAGENTS FOR AIDS THERAPY. |
FR2649120B1 (en) | 1989-06-30 | 1994-01-28 | Cayla | NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD |
EP0939121B2 (en) * | 1989-09-12 | 2007-12-26 | AHP Manufacturing B.V. | TNF-binding proteins |
CA2079880A1 (en) * | 1990-04-24 | 1991-10-25 | William E. Van Nostrand | Purification, detection and methods of use of protease nexin-2 |
US5213962A (en) * | 1990-04-24 | 1993-05-25 | The Regents Of The University Of California | Purification, detection and methods of use of protease Nexin-2 |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
MX9204374A (en) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION. |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5716805A (en) | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
WO1993010459A1 (en) * | 1991-11-12 | 1993-05-27 | The University Of Melbourne | A method for assaying and treating alzheimer's disease |
WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
DE69233528T2 (en) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Process for the preparation of multivalent antigen-binding proteins |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
CH682806A5 (en) | 1992-02-21 | 1993-11-30 | Medimpex Ets | Injection device. |
CA2086165A1 (en) * | 1992-04-09 | 1993-10-10 | Paul P. Tamburini | Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein |
US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
DE69308573T2 (en) | 1992-08-17 | 1997-08-07 | Genentech Inc | SPECIFIC IMMUNOADHESINE |
NZ257942A (en) | 1992-10-23 | 1996-04-26 | Immunex Corp | Preparing a mammalian protein by expression of a fusion protein containing a leucine zipper domain |
DE69420137T2 (en) | 1993-06-03 | 1999-12-23 | Therapeutic Antibodies Inc | PRODUCTION OF ANTIBODY FRAGMENTS |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US6140332A (en) | 1995-07-06 | 2000-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
ATE346303T1 (en) * | 1996-03-29 | 2006-12-15 | Univ Boston | METHODS FOR DIAGNOSIS, PRODUCTION OF MEDICATIONS AND SCREENING OF SUBSTANCES AS WELL AS BETA-AMYLOID DERIVED PEPTIDES ASSOCIATED WITH ALZHEIMER'S DISEASE |
PL190489B1 (en) | 1996-04-12 | 2005-12-30 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
ID18494A (en) | 1996-10-02 | 1998-04-16 | Novartis Ag | PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT |
US6013476A (en) * | 1997-04-02 | 2000-01-11 | Smithkline Beecham Corporation | DNA encoding tumor necrosis related receptor TR7 |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
CA2288705C (en) | 1997-05-06 | 2008-03-18 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
US6949358B1 (en) | 1997-06-11 | 2005-09-27 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor TR9 |
US6358508B1 (en) * | 1997-06-11 | 2002-03-19 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR9 |
IT1293511B1 (en) | 1997-07-30 | 1999-03-01 | Gentili Ist Spa | MONOCLONAL CATALYTIC ANTIBODIES WITH PROTEASIC ACTIVITY FOR THE SELECTIVE LYSIS OF THE PROTEIN COMPONENT OF PLATES AND RELATED AGGREGATES |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
US7378507B2 (en) * | 1997-09-18 | 2008-05-27 | Genentech, Inc. | PRO217 polypeptides |
US6194151B1 (en) * | 1997-09-26 | 2001-02-27 | Millenium Pharmaceuticals, Inc. | Molecules of the TNF receptor superfamily and uses therefor |
HUP0004286A3 (en) | 1997-11-06 | 2002-01-28 | American Cyanamid Co Madison | Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps |
US6916907B1 (en) * | 1998-10-23 | 2005-07-12 | Curagen Corporation | Nucleic acids encoding osteoprotegern-like proteins and methods of using same |
EA003786B1 (en) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
US6423494B1 (en) * | 1999-03-25 | 2002-07-23 | Millennium Pharmaceuticals, Inc. | DR6 and uses thereof |
WO2002077178A2 (en) * | 2001-03-23 | 2002-10-03 | University Of Utah Research Foundation | Method of screening for agents that regulate the shedding of membrane bound proteins and methods of use |
WO2003040183A2 (en) | 2001-11-09 | 2003-05-15 | The Genetics Company, Inc | Compounds for the diagnosis/prevention/treatment of alzheimer's disease |
EP1455825A4 (en) | 2001-12-17 | 2006-05-31 | Lilly Co Eli | Treating b-cell mediated diseases by modulating dr6 activity |
EP1444989A1 (en) * | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
EP1447093A1 (en) | 2003-02-14 | 2004-08-18 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries |
WO2005028511A2 (en) | 2003-03-28 | 2005-03-31 | Centocor, Inc. | Anti-amyloid antibodies, compositions, methods and uses |
EP1682170A2 (en) * | 2003-11-07 | 2006-07-26 | Lay Line Genomics SpA | Compositions able to prevent neurodegenerative processes and methods of assaying the same |
PL1720909T3 (en) | 2004-02-23 | 2012-04-30 | Lilly Co Eli | Anti-abeta antibody |
EP1841455A1 (en) | 2005-01-24 | 2007-10-10 | Amgen Inc. | Humanized anti-amyloid antibody |
ES2301280A1 (en) * | 2005-05-16 | 2008-06-16 | Fina Biotech S.L.U. | Method for the diagnosis of alzheimer's disease |
RS53270B2 (en) | 2005-11-30 | 2018-05-31 | Abbvie Deutschland | Monoclonal antibodies against amyloid beta protein and uses thereof |
JP5475994B2 (en) | 2005-11-30 | 2014-04-16 | アッヴィ・インコーポレイテッド | Anti-Aβ globulomer antibody, antigen-binding portion thereof, corresponding hybridoma, nucleic acid, vector, host cell, method for producing said antibody, composition comprising said antibody, use of said antibody and method of using said antibody. |
CN101541322A (en) * | 2006-07-28 | 2009-09-23 | 布朗歇特洛克菲勒神经科学研究所 | Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory |
KR20090094854A (en) * | 2006-12-22 | 2009-09-08 | 제넨테크, 인크. | Dr6 antibodies inhibiting the binding of dr6 to app, and uses thereof in treating neurological disorders |
US20100099609A1 (en) * | 2008-07-28 | 2010-04-22 | Buck Institute For Age Research | eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE |
CA2744043A1 (en) * | 2008-11-25 | 2010-06-03 | Biogen Idec Ma Inc. | Use of dr6 and p75 antagonists to promote survival of cells of the nervous system |
TW201034684A (en) * | 2009-02-18 | 2010-10-01 | Genentech Inc | Method for inhibiting neurodegeneration |
-
2010
- 2010-11-12 WO PCT/US2010/056506 patent/WO2011060246A2/en active Application Filing
- 2010-11-12 US US12/944,869 patent/US20110110942A1/en not_active Abandoned
- 2010-11-12 TW TW099139096A patent/TW201121570A/en unknown
- 2010-11-12 MX MX2012005464A patent/MX2012005464A/en not_active Application Discontinuation
- 2010-11-12 JP JP2012539011A patent/JP2013510871A/en active Pending
- 2010-11-12 KR KR1020127012195A patent/KR20120103587A/en not_active Application Discontinuation
- 2010-11-12 EP EP10779649A patent/EP2498817A2/en not_active Withdrawn
- 2010-11-12 RU RU2012124093/15A patent/RU2012124093A/en unknown
- 2010-11-12 AR ARP100104199A patent/AR078986A1/en unknown
- 2010-11-12 CA CA2780319A patent/CA2780319A1/en not_active Abandoned
- 2010-11-12 CN CN2010800512118A patent/CN102612374A/en active Pending
- 2010-11-12 BR BR112012009997A patent/BR112012009997A2/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2498817A2 (en) | 2012-09-19 |
WO2011060246A2 (en) | 2011-05-19 |
CA2780319A1 (en) | 2011-05-19 |
AR078986A1 (en) | 2011-12-14 |
US20110110942A1 (en) | 2011-05-12 |
WO2011060246A3 (en) | 2011-07-07 |
BR112012009997A2 (en) | 2019-09-24 |
KR20120103587A (en) | 2012-09-19 |
JP2013510871A (en) | 2013-03-28 |
CN102612374A (en) | 2012-07-25 |
TW201121570A (en) | 2011-07-01 |
MX2012005464A (en) | 2012-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2012124093A (en) | METHOD FOR INCREASING DENSITY OF DENDRITIC SPIKES | |
Babcock et al. | Cytokine-producing microglia have an altered beta-amyloid load in aged APP/PS1 Tg mice | |
US11912998B2 (en) | Method of treating aging-associated cognitive impairment by reducing CCR3 | |
Ritzel et al. | Aging alters the immunological response to ischemic stroke | |
US10626399B2 (en) | Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) | |
Zhang et al. | Lamotrigine attenuates deficits in synaptic plasticity and accumulation of amyloid plaques in APP/PS1 transgenic mice | |
Huang et al. | TGF-β1 blockade of microglial chemotaxis toward Aβ aggregates involves SMAD signaling and down-regulation of CCL5 | |
Frost et al. | Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study | |
Le Dreau et al. | NOV/CCN3 upregulates CCL2 and CXCL1 expression in astrocytes through β1 and β5 integrins | |
ATE474599T1 (en) | USE OF ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF MULTIPLE MYELOMA | |
JP2014530226A5 (en) | ||
CY1118551T1 (en) | Methods of Treating Autoimmune Disease with DLL4 Antagonists | |
RU2008137764A (en) | METHODS FOR PREVENTING AND TREATING AMYLOID DISEASES | |
EA201190042A1 (en) | IMIDAZOPIRAZINE INHIBITORS OF SYK THYROZINKINASE | |
EA201301293A1 (en) | APPLICATION OF ANTIBODIES AND FRAGMENTS OF ANTIBODIES AGAINST CGRP FOR PREVENTION OR INHIBITION OF LIGHT-BODY POINT OR ABUSE TO LIGHT IN SUBJECTS NEEDING THERE, IN FEATURES OF MIGREDIENTS | |
WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
Zhou et al. | IL‐2mAb reduces demyelination after focal cerebral ischemia by suppressing CD8+ T cells | |
Rimmerman et al. | Microglia and their LAG3 checkpoint underlie the antidepressant and neurogenesis-enhancing effects of electroconvulsive stimulation | |
DE602004028270D1 (en) | USE OF ANTAGONIST ANTI-CD40 ANTIBODIES FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA | |
JP2013506675A5 (en) | ||
Summers et al. | Adhesion to the extracellular matrix is required for interleukin-1 beta actions leading to reactive phenotype in rat astrocytes | |
van der Feen et al. | Converging paths of pulmonary arterial hypertension and cellular senescence | |
Tok et al. | Functional neurophysiological biomarkers of early-stage Alzheimer’s disease: A perspective of network hyperexcitability in disease progression | |
Cai et al. | Physiological roles of β-amyloid in regulating synaptic function: Implications for AD pathophysiology | |
Zheng et al. | Choroid plexus-selective inactivation of adenosine A2A receptors protects against T cell infiltration and experimental autoimmune encephalomyelitis |